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MM patients harbor phenotypic CD19
? B cells expressing the immunoglobulin gene sequence and the idiotype unique to the individual myeloma clone. Some previous studies have reported that CD19
? clonotypic B cells can serve as MM-initiating cells. However, we and another group have recently showed that CD19
? B cells from many MM patients do not reconstitute MM disease upon transplantation into NOD/SCID IL2Rcc -/-mice. In the SCID-rab and SCID-hu models, which enable engraftment of human MM in vivo, CD19
-CD38 ?? plasma cells engrafted and rapidly propagated MM, while engraftment of CD19
? B cells was not detected. Both CD138 -and CD138 ? plasma cells have the potential to propagate MM clones in vivo in the absence of CD19
? B cells. Distinct from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential.
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CD19
1 clonotypic B cells in MM patients
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells [1] [2] [3] . The immunoglobulin gene sequences in MM plasma cells are somatically hyper-mutated and remain constant throughout the clinical course, suggesting that the disease arises from a post-germinal center B cell or a more differentiated cell [4] [5] [6] (Fig. 1) . Previous studies have found that MM patients harbor phenotypic B cells expressing the immunoglobulin gene sequence and the idiotype unique to the individual myeloma clone [7] [8] [9] [10] . These findings imply that clonotypic B cells may be involved in the disease process but offer no definitive proof that B cells in fact correspond to the proliferating tumor compartment. We examined the expression of immunoglobulin light chain j and k in the CD19 ? B cells and CD19 -CD38 ?? plasma cells from MM patients, and found highly biased expression of j or k chain in CD19
? B cells in some patients, suggesting that clonal CD19
? B cells expanded in these patients. Morphological abnormality of CD19
? B cells were also observed in some patients (Fig. 2) . It is thus no doubt that clonotypic B cells can be found in MM patients, however, it has been unclear whether clonotypic B cells are MM-initiating cells or premalignant cells, which need additional oncogenic hits to become fully transformed MM-initiating cells.
MM-initiating potentials of CD19
1 clonotypic B cells could not be detected by xeno-transplant assay using NOD/SCIDXIL2Rc 2/2 mice in many MM patients
CD19
? B cells isolated from MM patients could reportedly generate MM disease upon transplantation into NOD/SCID mice in a few MM patients [11] [12] [13] [14] , indicating that clonotypic CD19
? B cells served as MM progenitor cells in these patients. These results suggested that CD19
? clonotypic B cells are important therapeutic targets in MM therapy. However, B cell depletion by means of rituximab in MM patients was not clinically effective in most cases, at least for short periods [15] . It is therefore still unclear whether CD19
? or CD20 ? clonogenic MM progenitor cells are responsible for disease progression and maintenance.
We transplanted purified CD19 ? B cells from peripheral blood (PB) or bone marrow (BM) of MM patients into immunodeficient mice. CD19
? B cells were FACS-sorted from PB or BM cells from MM patients and transplanted directly into BM of NOD/Shi-scid,IL-2Rcnull (NOG) mice or intravenously to new born pups of NOG mice [16] . Engraftment of human MM cells was monitored by measuring human immunoglobulin light chain (IgL) j and k in serum of the recipient mice, but no human IgL was detected at any time. We also analyzed BM of the recipient mice 12-20 weeks after transplant, but no human CD19
? or CD38
?? cells were detected (Fig. 3a) . CD19 -CD38
??
plasma cells from the MM BM samples were also transplanted into NOG mice, but did not engraft. In contrast, robust engraftment of human cells was observed upon transplantation of cord blood-derived CD34 ? cells (Fig. 3a) . In some experiments, CD3
-CD34 -CD138 -cells were transplanted into BM of NOG mice, but did not engraft. Finally, CD3-depleted BM cells from MM patients were transplanted intravenously into a newborn NOG mouse. When the BM cells were analyzed 12 weeks after transplant, significant engraftment of human CD45
? cells was observed because CD3
-BM cells contained many CD34 ? hematopoietic stem and progenitor cells. Small numbers of human CD38
?? CD138 ? plasma cells were also detected, but analysis of their IgL j and k expression showed that they were not clonal MM plasma cells (Fig. 3b) . This result suggests that normal human hematopoietic cells, but not MM cells engrafted in the recipient mice. Kim and Weissman [17] have recently reported that the similar results.
Taken together, the presence of CD19 ? MM-initiating cells could not be proven by xeno-transplant assay using (Fig. 4) . Importantly, these BM cells, which do not contain CD1 9? B cells, could be secondary transplanted to another SCID-rab recipient and propagate MM disease (Fig. 4) . These results indicate that both CD38
?? CD138 -and CD38 ?? CD138 -plasma cells, but not CD19
? B cells, contained MM-initiating cells, which have the potential to propagate and maintain MM clones, at least for several months, in the absence of clonotypic B cells. In some patients, highly proliferative MM progenitor cells were present in the CD138-negative fraction, but those cells were MM plasma cells, not B cells (Fig. 4) . CD138
-MM plasma cells may be enriched with immature and proliferative plasma cells. In consistent with this, Kawano et al. [20] ? clonotypic B cells (Fig. 5) .
Future prospects about studies about MM-initiating cells or MM stem cells
It is still unclear whether only a subset of plasma cells has MM-initiating potential or many plasma cells have it. It is well known that the survival of MM plasma cells is highly dependent on microenvironment [23, 24] [11] [12] [13] [14] , indicating that CD19
? B cells of these MM patients definitely contain MM progenitor cells. In our experiments [16] and those by Kim et al. [17] , CD19
? B cells from MM patients never induced MM disease upon transplantation into NOG mice. However, this does not necessarily mean that CD19
? clonotypic B cells cannot be MM progenitor cells in those MM patients. It should be noted that there are many difficulties involved in the engraftment of human cells in xeno-graft models. For example, mouse IL6, which is one of the major growth factors for plasma cells, does not transduce its signals through human IL6 receptors, and probably other factors also lack inter-species cross-reactivity between human and mice. This means that MM progenitor cells can be detected in xeno-graft assays only when they can survive independently of human IL6 or other human factors. Thus, CD19
? B cells from advanced MM patients may be independent of several survival factors and effectively engraft and propagate MM disease upon transplant into immuno-deficient mice. In addition, signals from B cell receptors (BCRs) on clonotypic CD19 ? MM progenitor cells are present, they can be detected in xenograft assays only when their BCRs are suitable for survival in mice.
While xeno-transplant system is hard to utilize in research for the stem cells of B cell malignancies for the reason as described above, it is an extremely excellent tool for the analysis of human hematopoietic stem cells. Numbers of excellent studies about normal or malignant hematopoietic stem cells have been done with xeno-transplantation to NOD/SCID or NOG mice. It is thus possible for us to analyze whether hematopoietic stem cells are normal in MM or other B cell malignancies. Kikushige and Akashi [27] have recently reported surprising results of the analysis of HSCs in CLL patients. They found that HSCs purified from patients with CLL displayed lymphoid-lineage gene priming and produced a high number of polyclonal B cell progenitors. Strikingly, their maturation into B cells was restricted always to mono-or oligo-clones with CLL-like phenotype in xenogeneic recipients. These results let us prompted us to perform the same analysis of HSCs from MM patients.
How to target MM-initiating cells in bone marrow
MM-initiating plasma cells should be considered important therapeutic targets, although we have not identified which plasma cells have MM-initiating potential. The Hedgehog signaling pathway was reported to be a promising candidate as a therapeutic target against clonogenic MM cells [28] . In addition, it is also important to understand the mechanisms involved in how the BM microenvironment supports clonogenic MM plasma cells and targets them. The Notch signaling pathway may be a good candidate for such a target [29] .
In addition to these, therapy with monoclonal antibody against MM plasma cells should be a promising strategy [30] . Since the mechanisms of antibody drug to kill tumor cells are totally different from those of other drugs such as chemotherapeutic drugs, proteasome inhibitors, and IMIDs, combination of antibody drugs with these conventional therapies should be effective. In fact, the addition of rituximab to CHOP chemotherapy increased the cure rate of lymphoma patients. Results of clinical trials with anti-CS1 antibody is very promising [31] , and thereby it is expected to be approved as the first antibody drug against MM. In addition, several other antibodies, for example anti-CD38 mAb [32] , have been also proved to be effective in MM patients.
We recently identified CD48 as a novel therapeutic target that is highly expressed on MM plasma cells in almost all MM patients (Fig. 5) [33] . In 22 out of 24 MM patients, CD48 was expressed on more than 90 % of MM plasma cells at significantly higher levels than it was on normal lymphocytes and monocytes. An anti-CD48 mAb that was newly generated by us induced antibody-dependent cell-mediated cytotoxicity and marked complementdependent cytotoxicity against not only MM cell lines but also primary MM plasma cells in vitro. ? long term-HSCs, in most of human CD34
? hematopoietic stem cells do not express or expressed at very low levels of CD48. These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM.
Conclusion
Different from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. This suggests that strategies for targeting MM-initiating cells should be different from those for leukemia-stem cells. On the other hand, some reports suggested common characters between MM plasma cells and hematopoietic stem cells. Especially, both of them highly prefer BM microenvironment. We now need to know how BM microenvironment supports MMinitiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model.
